Therapeutic Potential of Targeting the Ghrelin Pathway.
Therapeutic Potential of Targeting the Ghrelin Pathway.
复制标题
DOI：
10.3390/ijms18040798
复制
发表时间：
2017-04-11
影响因子：
5.6
通讯作者：
Müller TD
中科院分区：
文献类型：
--
作者：
Colldén G;Tschöp MH;Müller TD
Ghrelin于1999年被发现是生长激素促分泌素受体1a（GHSR1a）的内源性配体。从那时起，生长激素释放肽已被发现发挥过多的生理作用，远远超出其最初的特征作为生长激素（GH）促分泌素。生长激素释放肽的众多公认作用包括刺激食欲和脂质积累，调节免疫和炎症，刺激胃运动，改善心脏性能，调节应激、焦虑、味觉和奖赏寻求行为，以及调节葡萄糖代谢和产热。由于对系统代谢的多种有益作用，内源性生长激素释放肽系统的药理学靶向被广泛认为是治疗代谢并发症如慢性炎症、胃轻瘫或癌症相关厌食症和恶病质的有价值的方法。本文旨在讨论和强调生长激素释放肽通路调节在治疗厌食症、恶病质、肌肉减少症、心脏病、神经退行性疾病、肾脏和肺部疾病、胃肠道（GI）疾病、炎症性疾病和代谢综合征方面的广泛药理学潜力。
Ghrelin was discovered in 1999 as the endogenous ligand of the growth-hormone secretagogue receptor 1a (GHSR1a). Since then, ghrelin has been found to exert a plethora of physiological effects that go far beyond its initial characterization as a growth hormone (GH) secretagogue. Among the numerous well-established effects of ghrelin are the stimulation of appetite and lipid accumulation, the modulation of immunity and inflammation, the stimulation of gastric motility, the improvement of cardiac performance, the modulation of stress, anxiety, taste sensation and reward-seeking behavior, as well as the regulation of glucose metabolism and thermogenesis. Due to a variety of beneficial effects on systems’ metabolism, pharmacological targeting of the endogenous ghrelin system is widely considered a valuable approach to treat metabolic complications, such as chronic inflammation, gastroparesis or cancer-associated anorexia and cachexia. The aim of this review is to discuss and highlight the broad pharmacological potential of ghrelin pathway modulation for the treatment of anorexia, cachexia, sarcopenia, cardiopathy, neurodegenerative disorders, renal and pulmonary disease, gastrointestinal (GI) disorders, inflammatory disorders and metabolic syndrome.